Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapy

PURPOSE: Addition of rolapitant to standard antiemetic therapy improved protection against chemotherapy-induced nausea and vomiting (CINV) in phase 3 trials of patients receiving highly emetogenic chemotherapy (HEC) or moderately emetogenic chemotherapy (MEC). Here, we assessed the impact of CINV on...

Descripción completa

Detalles Bibliográficos
Autores principales: Chasen, Martin, Urban, Laszlo, Schnadig, Ian, Rapoport, Bernardo, Powers, Dan, Arora, Sujata, Navari, Rudolph, Schwartzberg, Lee, Gridelli, Cesare
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5127871/
https://www.ncbi.nlm.nih.gov/pubmed/27557833
http://dx.doi.org/10.1007/s00520-016-3388-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5127871/
https://www.ncbi.nlm.nih.gov/pubmed/27557833
http://dx.doi.org/10.1007/s00520-016-3388-7

Ejemplares similares